New prostate cancer treatments: Key physician takeaways
Prospective reviews and recent approvals highlight the impact of AR‑targeting agents (enzalutamide), PARP inhibition (olaparib, rucaparib) for BRCA‑mutated metastatic castration‑resistant prostate cancer, and Lutetium‑177 PSMA radioligand therapy for bone‑metastatic disease; these emerging therapies offer potential improvements in efficacy and quality of life for patients.
This review outlines recent therapeutic advances in prostate cancer, including the use of enzalutamide for hormone‑sensitive disease, PARP inhibitors such as olaparib for BRCA‑mutated metastatic castration‑resistant prostate cancer, and lutetium‑177 PSMA radioligand therapy for bone‑metastatic disease. Physician perspectives from the Sermo community highlight real‑world implementation and quality‑of‑life considerations.
Prostate cancer remains a leading cause of morbidity and mortality among men; newly approved, targeted treatments may improve survival outcomes and preserve quality of life for patients with advanced disease.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience